CRISPR Therapeutics AG (CRSP) Receivables - Net (2015 - 2024)

CRISPR Therapeutics AG has disclosed Receivables - Net across 10 years of filings, most recently posting $25.0 million for Q4 2024.

• Receivables - Net for Q4 2024 came in at $25.0 million, down 87.5% year-over-year; the trailing twelve-month figure through Dec 2024 was $25.0 million (down 87.5% YoY), and the FY2024 annual result was $25.0 million, down 87.5% from the prior year.
• Receivables - Net came in at $25.0 million for Q4 2024 at CRISPR Therapeutics AG, down from $200.0 million in the prior quarter.
• In the past five years, Receivables - Net ranged from a high of $200.0 million in Q4 2023 to a low of $33000.0 in Q2 2020.
• The 5-year median for Receivables - Net is $150000.0 (2021), against an average of $23.0 million.
• Across the five-year window, Receivables - Net slumped 99.4% in 2021 and jumped 105960.61% in 2023, its largest moves.
• CRISPR Therapeutics AG's Receivables - Net stood at $144000.0 in 2020, then surged by 111.81% to $305000.0 in 2021, then plunged by 83.93% to $49000.0 in 2022, then jumped by 408063.27% to $200.0 million in 2023, then tumbled by 87.5% to $25.0 million in 2024.
• The last three Receivables - Net figures came in at $25.0 million (Q4 2024), $200.0 million (Q4 2023), and $70.0 million (Q2 2023), per Business Quant data.